Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immune Recovery

Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study

Abstract

Post transplant infusion of donor-type natural killer (NK) cells has been shown to have an anti-leukemia-enhancing effect without evoking GVHD in murine hematopoietic cell transplantation (HCT) models. Here, we tested 14 patients (age, 23–65 years), 12 with acute leukemia and 2 with myelodysplastic syndrome, who underwent HLA-mismatched HCT and subsequently received donor NK cell infusions. Cell donors (age, 16–51 years), comprising seven siblings, five offspring, and two mothers of the patients, underwent growth factor-mobilized leukapheresis for 3–5 days. Cells collected on the first 2–4 days were used for HCT, whereas those collected on the last day were CD34 selected by magnetic-activated cell sorting (median, 2.22 × 106 cells/kg; range, 0.29–5.66). Donor NK cells were generated from the CD34+ cells by ex vivo cell culture over a 6-week period (median, 9.28 × 106 cells/kg; range, 0.33–24.50; CD122/CD56+ 64%; CD3+ 1.0%; and viability 88%). There were no signs of acute toxicity in patients infused with these cells 6–7 weeks post transplant. Overall, one and five patients developed acute and chronic GVHD during post transplant period, respectively. These results showed that clinical-grade donor NK cell production from CD34+ cells is feasible.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rosenberg EB, McCoy JL, Green SS, Donnelly FC, Siwarski DF, Levine PH et al. Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst 1974; 52: 345–352.

    Article  CAS  PubMed  Google Scholar 

  2. Herberman RB, Nunn ME, Holden HT, Lavrin DH . Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230–239.

    Article  CAS  PubMed  Google Scholar 

  3. Di Santo JP . Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257–286.

    Article  CAS  PubMed  Google Scholar 

  4. Caligiuri MA . Human natural killer cells. Blood 2008; 112: 461–469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–1947.

    Article  CAS  PubMed  Google Scholar 

  6. Verheyden S, Demanet C . NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249–257.

    Article  CAS  PubMed  Google Scholar 

  7. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–732.

    Article  CAS  PubMed  Google Scholar 

  8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  PubMed  Google Scholar 

  9. Lundqvist A, Philip McCoy J, Samsel L, Childs R . Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109: 3603–3606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gonzalez S, Groh V, Spies T . Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121–138.

    CAS  PubMed  Google Scholar 

  11. Parham P, McQueen KL . Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108–122.

    Article  CAS  PubMed  Google Scholar 

  12. Martin PJ . Overview of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation,, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 16–30.

    Google Scholar 

  13. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  14. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  PubMed  Google Scholar 

  15. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.

    Article  PubMed  Google Scholar 

  16. Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351–1357.

    Article  CAS  PubMed  Google Scholar 

  17. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–1084.

    Article  PubMed  Google Scholar 

  18. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–697.

    Article  CAS  PubMed  Google Scholar 

  19. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lee KH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61–72.

    Article  CAS  PubMed  Google Scholar 

  21. Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39–44.

    Article  CAS  PubMed  Google Scholar 

  22. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414–417.

    Article  PubMed  Google Scholar 

  23. Ljunggren HG, Malmberg KJ . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329–339.

    Article  CAS  PubMed  Google Scholar 

  24. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835–1838.

    Article  CAS  PubMed  Google Scholar 

  25. Schulze A, Schirutschke H, Oelschlagel U, Schmitz M, Fussel M, Wassmuth R et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008; 36: 378–389.

    Article  CAS  PubMed  Google Scholar 

  26. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641–653.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–3057.

    Article  CAS  PubMed  Google Scholar 

  28. Yoon SR, Chung JW, Choi I . Development of natural killer cells from hematopoietic stem cells. Mol Cells 2007; 24: 1–8.

    CAS  PubMed  Google Scholar 

  29. Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H et al. VDUP1 is required for the development of natural killer cells. Immunity 2005; 22: 195–208.

    Article  CAS  PubMed  Google Scholar 

  30. Mrozek E, Anderson P, Caligiuri MA . Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632–2640.

    CAS  PubMed  Google Scholar 

  31. Sullivan K . Graft-vs host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 635–664.

    Google Scholar 

  32. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  33. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al. KIR Ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828–836.

    Article  CAS  PubMed  Google Scholar 

  34. Remberger M, Sundberg B . Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005; 90: 931–938.

    CAS  PubMed  Google Scholar 

  35. Poggi A, Zocchi MR . Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun Rev 2005; 4: 532–536.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from the GRL project and the New Drug Target Discovery Project (M10848000352-08N4800-35210), the Ministry of Education, Science and Technology, Republic of Korea (IC and SRY).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to I Choi or K H Lee.

Ethics declarations

Competing interests

KHL received an honorarium for a lecture from Genzyme. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoon, S., Lee, Y., Yang, S. et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 45, 1038–1046 (2010). https://doi.org/10.1038/bmt.2009.304

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.304

Keywords

This article is cited by

Search

Quick links